I.Diabetes and Metabolic Disorder Background
Diabetes is a chronic disorder that affects how the body handles blood glucose, which is the major source of energy for the body's cells, notably the brain and muscles (Lema-Pérez, 2021) (Mergenthaler, 2013). It manifests in two ways: inadequate insulin production by the pancreas or the body's inability to utilize insulin properly. Insulin is a hormone that allows glucose to enter cells, where it is turned to energy.
There are two primary forms of diabetes:
● Type 1 diabetes is an autoimmune condition in which the immune system erroneously attacks and kills insulin-producing beta cells in the pancreas. As a result, people generate little or no insulin and must rely on insulin treatment throughout their lives to survive (Anderson, 2023). It usually appears in infancy or adolescence, however adult-onset instances may exist.
● Type 2 diabetes is distinguished by insulin resistance, a condition in which the body's cells do not respond appropriately to insulin. Initially, the pancreas adapts by making more insulin, but eventually, insulin production cannot keep up with the increased demand (Goyal, 2024). Type 2 diabetes is frequently associated with obesity, sedentary lifestyles, and eating choices.
Diabetes is classed as a metabolic condition since it causes abnormal glucose metabolism. Other metabolic diseases include metabolic syndrome, which combines obesity, hypertension, dyslipidemia, and insulin resistance. These metabolic abnormalities dramatically raise the risk of cardiovascular disease and associated consequences (Gao, 2025).
II.The Evolving Treatment Landscape for Type 1 Diabetes
Historically, insulin has been the foundation of Type 1 diabetes care. Insulin treatment, which was discovered in the early 1920s, has saved many lives. However, insulin therapy is neither a cure or disease-modifying treatment, but rather a management tool. While insulin efficiently decreases blood glucose levels, it does not treat the underlying autoimmune etiology of Type 1 diabetes (Saleem, 2025).
Over the last several decades, innovations in glucose monitoring, insulin delivery devices, and supplementary drugs have improved patients' quality of life and glucose management. Nonetheless, the evolution of autoimmune destruction of beta cells has gone neglected until recently.
III.The Breakthrough: Teplizumab
In November 2022, the United States Food and Drug Administration (FDA) approved Teplizumab (brand name: Tzield), the first disease-modifying medication for Type 1 diabetes (Evans-Molina, 2023). Teplizumab, developed by Provention Bio (later purchased by Sanofi), belongs to a novel class of immunomodulatory medicines that attempt to change the course of the illness rather than only manage symptoms (Sanofi, 2023).
Teplizumab is a monoclonal antibody that targets CD3, a protein located on the surface of T lymphocytes, which are responsible for the autoimmune destruction of pancreatic beta cells (Herold, 2019). Teplizumab, by modifying T cell activity, can slow the course of Type 1 diabetes in people at high risk of acquiring the illness.
Mechanism of Action
Teplizumab works by binding to T cell CD3 receptors, partially deactivating them, and diverting the immune response away from aggressive, beta cell-destroying activity. This immune regulation prolongs the function of insulin-producing beta cells, delaying the need for insulin therapy in high-risk individuals (Chatenoud, 2012).
Teplizumab, by lowering the autoimmune attack on the pancreas, provides a window of protection during a critical stage in the development of Type 1 diabetes, potentially changing long-term results for people who take it (Pozzilli, 2012).
Clinical Trials and Efficacy
The critical Phase 2 trial, NCT01030861, tested Teplizumab in relatives of Type 1 diabetes patients who had at least two diabetes-related autoantibodies and dysglycemia, suggesting a very high chance of developing clinica
(All Rights Reserved)